SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-18-050835
Filing Date
2018-08-09
Accepted
2018-08-09 10:29:15
Documents
50
Period of Report
2018-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q a18-14107_110q.htm 10-Q 1125048
2 EX-31.1 a18-14107_1ex31d1.htm EX-31.1 13645
3 EX-31.2 a18-14107_1ex31d2.htm EX-31.2 13600
4 EX-32.1 a18-14107_1ex32d1.htm EX-32.1 7027
5 EX-32.2 a18-14107_1ex32d2.htm EX-32.2 6845
  Complete submission text file 0001104659-18-050835.txt   3927292

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT nbrv-20180630.xml EX-101.INS 651146
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nbrv-20180630.xsd EX-101.SCH 31214
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT nbrv-20180630_cal.xml EX-101.CAL 38719
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT nbrv-20180630_def.xml EX-101.DEF 141802
10 XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT nbrv-20180630_lab.xml EX-101.LAB 320548
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nbrv-20180630_pre.xml EX-101.PRE 246576
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37558 | Film No.: 181003864
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences